HighTower Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

HighTower Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-34	Closed	-$5K	–	2539
2020 Q1	$5K	Buy	+34	New	+$5.31K	﹤0.01%	2147

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CWM

Cornerstone Wealth Management St. Peters, Missouri $2B AUM 19.19% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

HighTower Advisors's TTNP Position: Q2 2020 in Review

HighTower Advisors sold out of Titan Pharmaceuticals (TTNP) in Q2 2020, closing a stake of 34 shares — an estimated $5K sold.

HighTower Advisors first reported a position in TTNP in Q1 2020 and held it in 1 quarter. The position peaked at $5K in Q1 2020. 23 funds tracked by Wall St. Rank hold TTNP as of Q2 2020.

HighTower Advisors reported no remaining Titan Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
HighTower Advisors sold 34 Titan Pharmaceuticals shares in Q2 2020, an estimated $5K.
HighTower Advisors first reported a position in Titan Pharmaceuticals in Q1 2020 and held it in 1 quarter.
HighTower Advisors's Titan Pharmaceuticals position peaked at $5K in Q1 2020.
23 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2020.

Based on HighTower Advisors's 13F filing for Q2 2020, filed 10 Aug 2020.